AnaptysBio Inc. (NASDAQ:ANAB) broke out on 14 October at 20.37, and confirmed on 27 October at 27.93.
Thus, garnering a Strong Buy with a target price of 100 as all Key technical indicators have turned Very Bullish.
The Key support is at 20.22 and there is no overhead resistance.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation.
AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation.
The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was founded in Y 2005 and is HQ’d in San Diego, California.
Have a healthy day, Keep the Faith!
Latest posts by Paul Ebeling (see all)
- Sitting on a Cash Pile 10.0? Lots of People are Going to Fly Again Soon - January 21, 2021
- Wall Street’s Key Stock Analysts Research Report, All Buys - January 21, 2021
- Thursday’s World Stock Markets: Asia-Pacific - January 21, 2021